Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study

Aim To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods We enrolled 163 individuals with biopsy‐proven MAFLD undergoing transthoracic ech...

Full description

Saved in:
Bibliographic Details
Published inDiabetes, obesity & metabolism Vol. 26; no. 9; pp. 3684 - 3695
Main Authors Zhou, Xiao‐Dong, Xu, Cui‐Fang, Chen, Qin‐Fen, Shapiro, Michael D., Lip, Gregory Y. H., Chen, Li‐Li, Targher, Giovanni, Byrne, Christopher D., Tian, Na, Xiao, Tie, Huang, Chen‐Xiao, Ni, Yan, Zheng, Ming‐Hua
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.09.2024
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods We enrolled 163 individuals with biopsy‐proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra‐performance liquid chromatography coupled with tandem mass spectrometry. Results Among the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre‐HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status. Conclusions In this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy‐confirmed MAFLD.
AbstractList Aim To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods We enrolled 163 individuals with biopsy‐proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra‐performance liquid chromatography coupled with tandem mass spectrometry. Results Among the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre‐HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status. Conclusions In this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy‐confirmed MAFLD.
To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD).AIMTo analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD).We enrolled 163 individuals with biopsy-proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra-performance liquid chromatography coupled with tandem mass spectrometry.METHODSWe enrolled 163 individuals with biopsy-proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra-performance liquid chromatography coupled with tandem mass spectrometry.Among the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre-HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status.RESULTSAmong the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre-HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status.In this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy-confirmed MAFLD.CONCLUSIONSIn this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy-confirmed MAFLD.
To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). We enrolled 163 individuals with biopsy-proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra-performance liquid chromatography coupled with tandem mass spectrometry. Among the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre-HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status. In this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy-confirmed MAFLD.
AimTo analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD).MethodsWe enrolled 163 individuals with biopsy‐proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular ejection fraction >50% with at least one echocardiographic feature of HF (left ventricular diastolic dysfunction, abnormal left atrial size) and at least one HF sign or symptom. Serum levels of 38 BAs were analysed using ultra‐performance liquid chromatography coupled with tandem mass spectrometry.ResultsAmong the 163 patients enrolled (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) and 43 (26.4%) met the HFpEF and pre‐HFpEF criteria, and 38 serum BAs were detected. Serum ursodeoxycholic acid (UDCA) and hyocholic acid (HCA) species were lower in patients with HFpEF and achieved statistical significance after correction for multiple comparisons. Furthermore, decreases in glycoursodeoxycholic acid and tauroursodeoxycholic acid were associated with HF status.ConclusionsIn this exploratory study, specific UDCA and HCA species were associated with HFpEF status in adults with biopsy‐confirmed MAFLD.
Author Huang, Chen‐Xiao
Zheng, Ming‐Hua
Tian, Na
Xu, Cui‐Fang
Shapiro, Michael D.
Chen, Li‐Li
Zhou, Xiao‐Dong
Targher, Giovanni
Ni, Yan
Chen, Qin‐Fen
Lip, Gregory Y. H.
Byrne, Christopher D.
Xiao, Tie
Author_xml – sequence: 1
  givenname: Xiao‐Dong
  orcidid: 0000-0002-8534-0818
  surname: Zhou
  fullname: Zhou, Xiao‐Dong
  organization: The First Affiliated Hospital of Wenzhou Medical University
– sequence: 2
  givenname: Cui‐Fang
  surname: Xu
  fullname: Xu, Cui‐Fang
  organization: National Clinical Research Center for Child Health
– sequence: 3
  givenname: Qin‐Fen
  orcidid: 0000-0001-6596-5004
  surname: Chen
  fullname: Chen, Qin‐Fen
  organization: Wenzhou Medical University
– sequence: 4
  givenname: Michael D.
  surname: Shapiro
  fullname: Shapiro, Michael D.
  organization: Wake Forest University School of Medicine
– sequence: 5
  givenname: Gregory Y. H.
  orcidid: 0000-0002-7566-1626
  surname: Lip
  fullname: Lip, Gregory Y. H.
  organization: Aalborg University
– sequence: 6
  givenname: Li‐Li
  surname: Chen
  fullname: Chen, Li‐Li
  organization: The First Affiliated Hospital of Wenzhou Medical University
– sequence: 7
  givenname: Giovanni
  orcidid: 0000-0002-4325-3900
  surname: Targher
  fullname: Targher, Giovanni
  organization: IRCCS Sacro Cuore – Don Calabria Hospital
– sequence: 8
  givenname: Christopher D.
  orcidid: 0000-0001-6322-7753
  surname: Byrne
  fullname: Byrne, Christopher D.
  organization: University Hospital Southampton, University of Southampton, Southampton General Hospital
– sequence: 9
  givenname: Na
  orcidid: 0009-0007-3543-8036
  surname: Tian
  fullname: Tian, Na
  organization: The First Affiliated Hospital of Wenzhou Medical University
– sequence: 10
  givenname: Tie
  orcidid: 0009-0007-5630-8759
  surname: Xiao
  fullname: Xiao, Tie
  organization: The First Affiliated Hospital of Wenzhou Medical University
– sequence: 11
  givenname: Chen‐Xiao
  orcidid: 0009-0008-5427-5401
  surname: Huang
  fullname: Huang, Chen‐Xiao
  organization: The First Affiliated Hospital of Wenzhou Medical University
– sequence: 12
  givenname: Yan
  orcidid: 0000-0003-1779-7266
  surname: Ni
  fullname: Ni, Yan
  email: yanni617@zju.edu.cn
  organization: National Clinical Research Center for Child Health
– sequence: 13
  givenname: Ming‐Hua
  orcidid: 0000-0003-4984-2631
  surname: Zheng
  fullname: Zheng, Ming‐Hua
  email: zhengmh@wmu.edu.cn
  organization: Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38874096$$D View this record in MEDLINE/PubMed
BookMark eNp9kctu1TAQhi1URC-w4AWQJTZlkdaXXNlV5SoVdQGso4k9Vn2UxMF2WrLjEXidvk6fBJ-TglAl8Ma_x9-Mrf8_JHujG5GQ55yd8LROtRtOeFGx5hE54HkpMy5FubfTIqsbJvbJYQgbxlgu6-oJ2Zd1XeWsKQ_I7Wf080A72yMFZTWdvDPpECj4VAnBKQsRNb2x8YpeIfhIDdh-Tre70uQxoL9OBG5QRetGajyswo50gmhxjGGFB4zQud4qqpdg5nGH3f34-dc7BmJcaG-v0VNtA0LA1_RspPh96p2H6PxCQ5z18pQ8NtAHfHa_H5Gv795-Of-QXVy-_3h-dpEpWcgmk8KwXEihuBZaJWMK3Yi86UwJiiHjSvCSN6pidWEAQWLZgUHJjYKktJBH5Hidm5z5NmOI7WCDwr6HEd0cWsnKuip4wcuEvnyAbtzsx_S7RNVVw-tabqkX99TcDajbydsB_NL-DiUBr1ZAeReCR_MH4azdBt6mwNtd4Ik9fcAqG2Fra_Qppv913KSYl3-Pbt9cflo7fgGVq8Hx
CitedBy_id crossref_primary_10_1080_07853890_2024_2442535
crossref_primary_10_1016_j_cca_2024_120004
crossref_primary_10_3390_biom14070841
crossref_primary_10_1097_CP9_0000000000000106
crossref_primary_10_3390_ijms26052242
crossref_primary_10_1002_ehf2_15097
Cites_doi 10.1007/s13238-020-00804-9
10.1002/ejhf.2333
10.1016/j.bbadis.2017.12.039
10.1016/j.cmet.2020.11.017
10.1007/s12072-023-10543-8
10.1161/JAHA.121.021654
10.1002/hep.28707
10.1111/1755-5922.12462
10.1016/j.cardfail.2017.06.007
10.1002/hep.28431
10.3390/antiox11091822
10.1016/S0140-6736(14)61933-4
10.3390/biom8040159
10.1002/hep.28890
10.1111/jgh.14894
10.1111/dom.15014
10.1002/cbf.3303
10.1016/j.immuni.2016.10.009
10.1161/JAHA.123.032997
10.1111/dom.15016
10.1038/s41575-023-00846-4
10.1007/s11906-023-01242-8
10.1016/j.jacc.2021.11.007
10.1016/j.scib.2024.01.006
10.1161/JAHA.119.014279
10.1186/s12933-022-01697-0
10.1007/s00392-023-02371-5
10.1097/HJH.0000000000002716
10.21037/hbsn-22-421
10.1038/s41586-019-1865-0
ContentType Journal Article
Copyright 2024 John Wiley & Sons Ltd.
Copyright_xml – notice: 2024 John Wiley & Sons Ltd.
DBID AAYXX
CITATION
NPM
7T5
7TK
H94
K9.
7X8
DOI 10.1111/dom.15709
DatabaseName CrossRef
PubMed
Immunology Abstracts
Neurosciences Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1463-1326
EndPage 3695
ExternalDocumentID 38874096
10_1111_dom_15709
DOM15709
Genre researchArticle
Journal Article
GrantInformation_xml – fundername: High Level Creative Talents from Department of Public Health in Zhejiang Province
  funderid: S2032102600032
– fundername: Southampton National Institute for Health and Care Research (NIHR) Biomedical Research Centre
  funderid: NIHR203319
– fundername: School of Medicine, University of Verona
– fundername: National Natural Science Foundation of China
  funderid: 82070588; 82370577
– fundername: Southampton National Institute for Health and Care Research (NIHR) Biomedical Research Centre
  grantid: NIHR203319
– fundername: High Level Creative Talents from Department of Public Health in Zhejiang Province
  grantid: S2032102600032
– fundername: National Natural Science Foundation of China
  grantid: 82070588
– fundername: National Natural Science Foundation of China
  grantid: 82370577
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OC
29F
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
TEORI
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
NPM
7T5
7TK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
H94
K9.
7X8
ID FETCH-LOGICAL-c3539-32f04232c1d2dc1325d9249bf6ac0e01c21619c7085faea3e6bafe31fca6bad23
IEDL.DBID DR2
ISSN 1462-8902
1463-1326
IngestDate Fri Jul 11 11:38:44 EDT 2025
Sun Jul 13 03:20:33 EDT 2025
Thu Apr 03 07:07:43 EDT 2025
Thu Apr 24 23:10:27 EDT 2025
Tue Jul 01 02:58:18 EDT 2025
Wed Jan 22 17:17:51 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords metabolic dysfunction‐associated fatty liver disease
heart failure with preserved ejection fraction
bile acids profile
Language English
License 2024 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3539-32f04232c1d2dc1325d9249bf6ac0e01c21619c7085faea3e6bafe31fca6bad23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8534-0818
0000-0001-6596-5004
0000-0002-4325-3900
0009-0007-3543-8036
0000-0002-7566-1626
0000-0003-4984-2631
0009-0007-5630-8759
0000-0003-1779-7266
0000-0001-6322-7753
0009-0008-5427-5401
PMID 38874096
PQID 3087918836
PQPubID 1006516
PageCount 12
ParticipantIDs proquest_miscellaneous_3068751516
proquest_journals_3087918836
pubmed_primary_38874096
crossref_primary_10_1111_dom_15709
crossref_citationtrail_10_1111_dom_15709
wiley_primary_10_1111_dom_15709_DOM15709
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2024
PublicationDateYYYYMMDD 2024-09-01
PublicationDate_xml – month: 09
  year: 2024
  text: September 2024
PublicationDecade 2020
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: England
– name: Oxford
PublicationTitle Diabetes, obesity & metabolism
PublicationTitleAlternate Diabetes Obes Metab
PublicationYear 2024
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
References 2023; 14
2023; 11
2023; 12
2023; 17
2017; 65
2015; 385
2017; 23
2022; 24
2020; 35
2022; 21
2024; 13
2022; 145
2018; 8
2021; 10
2018; 1864
2023; 25
2021; 12
2021; 33
2021; 39
2017; 35
2020; 9
2016; 64
2022; 79
2020; 577
2024; 21
2024; 113
2022; 11
2024; 69
2024; 29
2018; 36
2016; 45
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
Zhou XD (e_1_2_10_16_1) 2024; 13
e_1_2_10_2_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
Yu W (e_1_2_10_35_1) 2023; 11
e_1_2_10_6_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
Zhang S (e_1_2_10_26_1) 2023; 14
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
Miao L (e_1_2_10_4_1) 2024; 29
e_1_2_10_29_1
Heidenreich PA (e_1_2_10_9_1) 2022; 145
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
References_xml – volume: 29
  start-page: S1043
  year: 2024
  end-page: S2760
  article-title: Current status and future trends of the global burden of MASLD
  publication-title: Trends Endocrinol Metab
– volume: 69
  start-page: 850
  year: 2024
  end-page: 852
  article-title: From HFpEF to "metabolic (dysfunction)‐associated HFpEF": time to act
  publication-title: Sci Bull (Beijing)
– volume: 23
  start-page: 666
  year: 2017
  end-page: 671
  article-title: Increased secondary/primary bile acid ratio in chronic heart failure
  publication-title: J Card Fail
– volume: 24
  start-page: 4
  year: 2022
  end-page: 131
  article-title: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the heart failure association (HFA) of the ESC
  publication-title: Eur J Heart Fail
– volume: 21
  start-page: 46
  year: 2024
  end-page: 56
  article-title: Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 79
  start-page: 180
  year: 2022
  end-page: 191
  article-title: Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week
  publication-title: J Am Coll Cardiol
– volume: 35
  start-page: 1057
  year: 2020
  end-page: 1064
  article-title: Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease
  publication-title: J Gastroenterol Hepatol
– volume: 35
  start-page: 453
  year: 2017
  end-page: 463
  article-title: Ursodeoxycholic acid protects cardiomyocytes against cobalt chloride induced hypoxia by regulating transcriptional mediator of cells stress hypoxia inducible factor 1α and p53 protein
  publication-title: Cell Biochem Funct
– volume: 65
  start-page: 189
  year: 2017
  end-page: 201
  article-title: Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart
  publication-title: Hepatology
– volume: 113
  start-page: 761
  year: 2024
  end-page: 769
  article-title: Clinical characteristics and prognosis of patients with hypertrophic cardiomyopathy and heart failure with preserved ejection fraction
  publication-title: Clin Res Cardiol
– volume: 65
  start-page: 813
  year: 2017
  end-page: 827
  article-title: G‐protein‐coupled bile acid receptor plays a key role in bile acid metabolism and fasting‐induced hepatic steatosis in mice
  publication-title: Hepatology
– volume: 21
  start-page: 270
  year: 2022
  article-title: Metabolic dysfunction‐associated fatty liver disease and implications for cardiovascular risk and disease prevention
  publication-title: Cardiovasc Diabetol
– volume: 11
  start-page: 1822
  year: 2022
  article-title: NADPH oxidases in diastolic dysfunction and heart failure with preserved ejection fraction
  publication-title: Antioxidants (Basel)
– volume: 17
  start-page: 773
  year: 2023
  end-page: 791
  article-title: An international multidisciplinary consensus statement on MAFLD and the risk of CVD
  publication-title: Hepatol Int
– volume: 25
  start-page: 13
  issue: Suppl 1
  year: 2023
  end-page: 26
  article-title: Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: a narrative review
  publication-title: Diabetes Obes Metab
– volume: 9
  year: 2020
  article-title: Longitudinal association of non‐alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study
  publication-title: J Am Heart Assoc
– volume: 577
  start-page: 410
  year: 2020
  end-page: 415
  article-title: Microbial bile acid metabolites modulate gut RORγ regulatory T cell homeostasis
  publication-title: Nature
– volume: 39
  start-page: 961
  year: 2021
  end-page: 969
  article-title: Fatty liver index and left ventricular mass: prospective associations from two independent cohorts
  publication-title: J Hypertens
– volume: 25
  start-page: 1421
  year: 2023
  end-page: 1433
  article-title: Nonalcoholic fatty liver disease from a primary care perspective
  publication-title: Diabetes Obes Metab
– volume: 13
  year: 2024
  article-title: High‐sensitivity C‐reactive protein is associated with heart failure hospitalization in patients with metabolic dysfunction‐associated fatty liver disease and normal left ventricular ejection fraction undergoing coronary angiography
  publication-title: J Am Heart Assoc
– volume: 12
  start-page: 411
  year: 2021
  end-page: 425
  article-title: Targeting the alternative bile acid synthetic pathway for metabolic diseases
  publication-title: Protein Cell
– volume: 8
  start-page: 159
  year: 2018
  article-title: Overview of bile acids signaling and perspective on the signal of Ursodeoxycholic acid, the most hydrophilic bile acid, in the heart
  publication-title: Biomolecules
– volume: 36
  year: 2018
  article-title: TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure‐induced stress in mice
  publication-title: Cardiovasc Ther
– volume: 385
  start-page: 956
  year: 2015
  end-page: 965
  article-title: Farnesoid X nuclear receptor ligand obeticholic acid for non‐cirrhotic, non‐alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo‐controlled trial
  publication-title: Lancet
– volume: 12
  start-page: 386
  year: 2023
  end-page: 403
  article-title: An international Delphi consensus statement on metabolic dysfunction‐associated fatty liver disease and risk of chronic kidney disease
  publication-title: Hepatobiliary Surg Nutr
– volume: 33
  start-page: 791
  year: 2021
  end-page: 803.e7
  article-title: Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism
  publication-title: Cell Metab
– volume: 64
  start-page: 73
  year: 2016
  end-page: 84
  article-title: Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes
  publication-title: Hepatology
– volume: 11
  start-page: 442
  year: 2023
  article-title: The interaction of gut microbiota and heart failure with preserved ejection fraction: from mechanism to potential therapies
  publication-title: Biomedicine
– volume: 10
  year: 2021
  article-title: Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries
  publication-title: J Am Heart Assoc
– volume: 1864
  start-page: 1345
  year: 2018
  end-page: 1355
  article-title: Heart and bile acids–clinical consequences of altered bile acid metabolism
  publication-title: Biochim Biophys Acta Mol Basis Dis
– volume: 145
  start-page: e895
  year: 2022
  end-page: e1032
  article-title: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
  publication-title: Circulation
– volume: 25
  start-page: 151
  year: 2023
  end-page: 162
  article-title: Mechanisms linking metabolic‐associated fatty liver disease (MAFLD) to cardiovascular disease
  publication-title: Curr Hypertens Rep
– volume: 14
  start-page: 261
  year: 2023
  end-page: 282
  article-title: The role of bile acids in cardiovascular diseases: from mechanisms to clinical implications
  publication-title: Aging Dis
– volume: 45
  start-page: 944
  year: 2016
  article-title: Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome
  publication-title: Immunity
– volume: 11
  start-page: 442
  year: 2023
  ident: e_1_2_10_35_1
  article-title: The interaction of gut microbiota and heart failure with preserved ejection fraction: from mechanism to potential therapies
  publication-title: Biomedicine
– ident: e_1_2_10_20_1
  doi: 10.1007/s13238-020-00804-9
– ident: e_1_2_10_25_1
  doi: 10.1002/ejhf.2333
– ident: e_1_2_10_28_1
  doi: 10.1016/j.bbadis.2017.12.039
– ident: e_1_2_10_34_1
  doi: 10.1016/j.cmet.2020.11.017
– ident: e_1_2_10_7_1
  doi: 10.1007/s12072-023-10543-8
– ident: e_1_2_10_13_1
  doi: 10.1161/JAHA.121.021654
– ident: e_1_2_10_19_1
  doi: 10.1002/hep.28707
– ident: e_1_2_10_31_1
  doi: 10.1111/1755-5922.12462
– volume: 29
  start-page: S1043
  year: 2024
  ident: e_1_2_10_4_1
  article-title: Current status and future trends of the global burden of MASLD
  publication-title: Trends Endocrinol Metab
– ident: e_1_2_10_23_1
  doi: 10.1016/j.cardfail.2017.06.007
– ident: e_1_2_10_2_1
  doi: 10.1002/hep.28431
– ident: e_1_2_10_30_1
  doi: 10.3390/antiox11091822
– ident: e_1_2_10_22_1
  doi: 10.1016/S0140-6736(14)61933-4
– ident: e_1_2_10_27_1
  doi: 10.3390/biom8040159
– ident: e_1_2_10_33_1
  doi: 10.1002/hep.28890
– ident: e_1_2_10_24_1
  doi: 10.1111/jgh.14894
– ident: e_1_2_10_5_1
  doi: 10.1111/dom.15014
– ident: e_1_2_10_29_1
  doi: 10.1002/cbf.3303
– ident: e_1_2_10_32_1
  doi: 10.1016/j.immuni.2016.10.009
– volume: 13
  year: 2024
  ident: e_1_2_10_16_1
  article-title: High‐sensitivity C‐reactive protein is associated with heart failure hospitalization in patients with metabolic dysfunction‐associated fatty liver disease and normal left ventricular ejection fraction undergoing coronary angiography
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.123.032997
– ident: e_1_2_10_6_1
  doi: 10.1111/dom.15016
– volume: 14
  start-page: 261
  year: 2023
  ident: e_1_2_10_26_1
  article-title: The role of bile acids in cardiovascular diseases: from mechanisms to clinical implications
  publication-title: Aging Dis
– ident: e_1_2_10_3_1
  doi: 10.1038/s41575-023-00846-4
– ident: e_1_2_10_15_1
  doi: 10.1007/s11906-023-01242-8
– volume: 145
  start-page: e895
  year: 2022
  ident: e_1_2_10_9_1
  article-title: 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
  publication-title: Circulation
– ident: e_1_2_10_11_1
  doi: 10.1016/j.jacc.2021.11.007
– ident: e_1_2_10_10_1
  doi: 10.1016/j.scib.2024.01.006
– ident: e_1_2_10_18_1
  doi: 10.1161/JAHA.119.014279
– ident: e_1_2_10_14_1
  doi: 10.1186/s12933-022-01697-0
– ident: e_1_2_10_12_1
  doi: 10.1007/s00392-023-02371-5
– ident: e_1_2_10_17_1
  doi: 10.1097/HJH.0000000000002716
– ident: e_1_2_10_8_1
  doi: 10.21037/hbsn-22-421
– ident: e_1_2_10_21_1
  doi: 10.1038/s41586-019-1865-0
SSID ssj0004387
Score 2.4709132
Snippet Aim To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic...
To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic...
AimTo analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients with metabolic...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3684
SubjectTerms Acids
bile acids profile
Biopsy
Congestive heart failure
Echocardiography
Ejection fraction
Fatty liver
Heart diseases
Heart failure
heart failure with preserved ejection fraction
Liquid chromatography
Liver diseases
Mass spectroscopy
metabolic dysfunction‐associated fatty liver disease
Metabolism
Serum levels
Tauroursodeoxycholic acid
Ursodeoxycholic acid
Ventricle
Title Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fdom.15709
https://www.ncbi.nlm.nih.gov/pubmed/38874096
https://www.proquest.com/docview/3087918836
https://www.proquest.com/docview/3068751516
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwELYQh4pLC6U_29JqqDhwyWodb8KGnlBbhJC2laoicagU-VdauputNtkDnHgEXofX6ZN0xnZSoEWquFn2JE7kGXvG_vwNYzsqc8bwgU5GgmOAYqxNVGp4wp0nNOPCeZ7t8ef86GR4fJqdrrD37V2YwA_RbbiRZfj5mgxcqvqGkZv5rM-zPX95j7Ba5BB9_UMdNRQ-OR5OBGjxBaF41lsUT_fk7bXoLwfztr_qF5zDJ-x7-6kBZ_Kjv2xUX1_cYXF84L-ss8fREYWDoDkbbMVWT9mjcTxq32TXOIssZ6DwfSD1xEDM7l2DXGBNHFVrgHZygfJiN-DkhFDuoYoQtgSnNGDPPN6rArcI1yhgUkEkdK2D8Mw2qI3TiQZzXtNaS2K_Lq9u9ONk05zDlHAkEI-V9uGgAutRhB4sAJ4s9xk7Ofz07cNREvM8JFpkokhE6gidk2puUqMxPM4MRYXK5VIP7IDrFJWm0HvoHTpppbC5ks4K7rTEkknFc7ZazSv7koFznELIocHCUA6cUiKzWW5xqpKZyU2P7bYjXupIgk65OKZlGwzhUJR-KHrsXSf6MzB__Etoq1WbMhp_XRLJYsFHI5H32HbXjGZLZzGysvMlyeQYKaK7hTIvgrp1vYgR5UkssGXXK8393Zcfv4x94dX_i75mayk6ZgEnt8VWm8XSvkHHqlFvvQX9BtsiJNI
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELaqVgIutPyVhQID4tBLVut4k24qLhWlWqBbJNRKvaDIv9LCbhbtZg_lxCPwOn2dPklnbCe0_EiIm2VP4kSesWfsz98w9lJlzhje08lAcAxQjLWJSg1PuPOEZlw4z7M9OsqHJ_13p9npCnvV3IUJ_BDthhtZhp-vycBpQ_qKlZvZtMuzHbq9t0YZvYk5f__jT_KovvDp8XAqQJsvCMez0eB42kevr0a_uZjXPVa_5Byss0_NxwakyZfuslZd_e0XHsf__ZsNdjv6orAXlOcOW7HVXXZjFE_b77FznEiWU1D4QpB6bCAm-F6AnGNNHFhrgDZzgVJj1-DkmIDuoYpAtoSoNGA_e8hXBW4eblLAuILI6boIwlNbo0JOxhrM2YKWWxK7-P7jSj9O1vUZTAhKAvFkaRf2KrAeSOjxAuD5cu-zk4M3x6-HSUz1kGiRiSIRqSOATqq5SY3GCDkzFBgql0vdsz2uU9SbQu-gg-iklcLmSjoruNMSSyYVD9hqNavsQwbOcYoi-wYLfdlzSonMZrnF2UpmJjcdtt0MeakjDzql45iUTTyEQ1H6oeiwF63o10D-8SehrUZvymj_i5J4Fgs-GIi8w563zWi5dBwjKztbkkyOwSJ6XCizGfSt7UUMKFVigS3bXmv-3n25_2HkC4_-XfQZuzk8Hh2Wh2-P3j9mt1L00wJsbout1vOlfYJ-Vq2eenO6BPmnKO4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIlVcoOXVhRYGxKGXrOI4STf0VLGsymMLQlTqASnyU1rYzVa72UM58RP4O_07_BJm7CS0PCTEzbIncSLP2DP2528Ye6oyZwyPdTQQHAMUY22kEsMj7jyhGRfO82yPj_Ojk_TVaXa6xg7auzCBH6LbcCPL8PM1GfiZcZeM3MxnfZ7t0-W9a2keF5S3Yfj-J3dUKnx2PJwJ0OQLgvFstjCe7tGri9FvHuZVh9WvOKOb7GP7rQFo8rm_qlVff_mFxvE_f2aT3Wg8UTgMqrPF1mx1i22Mm7P22-wCp5HVDBS-D6SeGGjSey9BLrCmGVZrgLZygRJj1-DkhGDuoYogtoSnNGA_ecBXBW4R7lHApIKG0XUZhGe2RnWcTjSY8yUttiT2_eu3S_04WdfnMCUgCTTnSs_gsALrYYQeLQCeLfcOOxm9-PD8KGoSPURaZKKIROIInpNobhKjMT7ODIWFyuVSxzbmOkGtKfQ-uodOWilsrqSzgjstsWQScZetV_PKbjNwjlMMmRospDJ2SonMZrnFuUpmJjc9tteOeKkbFnRKxjEt22gIh6L0Q9FjTzrRs0D98SehnVZtysb6lyWxLBZ8MBB5jz3umtFu6TBGVna-IpkcQ0X0t1DmXlC3rhcxoESJBbbseaX5e_fl8O3YF-7_u-gjtvFuOCrfvDx-_YBdT9BJC5i5HbZeL1Z2F52sWj30xvQDc2InnQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+bile+acid+profiles+are+associated+with+heart+failure+with+preserved+ejection+fraction+in+patients+with+metabolic+dysfunction%E2%80%90associated+fatty+liver+disease%3A+An+exploratory+study&rft.jtitle=Diabetes%2C+obesity+%26+metabolism&rft.au=Zhou%2C+Xiao%E2%80%90Dong&rft.au=Xu%2C+Cui%E2%80%90Fang&rft.au=Chen%2C+Qin%E2%80%90Fen&rft.au=Shapiro%2C+Michael+D.&rft.date=2024-09-01&rft.issn=1462-8902&rft.eissn=1463-1326&rft.volume=26&rft.issue=9&rft.spage=3684&rft.epage=3695&rft_id=info:doi/10.1111%2Fdom.15709&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_dom_15709
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-8902&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-8902&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-8902&client=summon